Shop MDUK Professionals

Helpline 0800 652 6352

Conditions

We’re the leading charity for over 60 muscle wasting and weakening conditions.  Connecting more than 110,000 people affected, and those around us.

What is muscular dystrophy?

Just diagnosed?

We are here for you from the point of diagnosis and beyond.

If you're in need of support, we're here to help.

Support and information

Our online community continues to grow, and we have multiple platforms for support.

Ways we support you

Our support services

Financial support

Support with bereavement, grief, and loss

Support groups and events

Support for parents and carers

Information

Information for living with a condition

Information days

Managing your condition

Housing adaptations and equipment

Discover our support groups

Whether you’re looking to find support in-person, or online, we’ve got a support group for you.

Get involved

Corporate partnerships

Fundraise your way

Leave a gift in your Will

Our latest events

Whether it’s a run, cycle or skydive you’re after – we have an event to suit you.

Run the Cambridge 10k 2026

Run our award-winning Bidwells Cambridge 10k route in 2026!

Research

Our research projects

Take part in research

For researchers

Our achievements

Latest research news

Learn more about research

Visit our hub and gain valuable insights into the world of modern science.

About Us

News and Updates

Read real life stories from people in the muscle wasting and weakening community.

Discover our ten-year strategy

We’re setting a clear, long-term direction for the future — one that’s powered by purpose, backed by evidence, and shaped by the voices of those we are here to support.

NEWS and UPDATES

September 2, 2026

A new treatment for TK2d is now available in the UK through the Early Access to Medicines Scheme. Doxecitine-doxribtimine is the first medicine developed specifically to target the underlying cause of TK2d.

ALL NEWS

Filter by type

New TK2d treatment available through UK early access scheme

September 2, 2026

Major £1.5m funding boost into muscle wasting conditions

September 2, 2026

Funding new research to understand the scale of neuromuscular conditions

August 18, 2026

Orange background with white text that reads 'Treatment update'

Myasthenia gravis treatment approved for NHS use in Scotland

August 10, 2026

Orange background with white text that reads 'Treatment update'

OAV101-IT, a potential new gene therapy for SMA, not yet recommended for NHS use in England

Newborn baby being held by a healthcare professional shortly after birth.

Every newborn baby in England to be screened for SMA

Graphic with the text: "PIP 'not fit for purpose', Timms Review says".

PIP ‘not fit for purpose’, Timms Review says

Collaborating with breast cancer awareness charity CoppaFeel!

SMA newborn screening debated in Parliament

New grant fund available for home equipment

Orange background with white text that reads 'Treatment update'

Translarna not accepted for routine use on the NHS in Scotland

Sign our petition for a benefits system that supports everyone living with a muscle wasting condition